NKP-1339 (Synonyms: KP1339) |
| カタログ番号GC19263 |
NKP-1339 (IT-139; KP-1339) は、限られた副作用で固形がんに対して開発中のクラス初のルテニウムベースの抗がん剤です。 NKP-1339 は、ミトコンドリア経路を介して、G2/M 細胞周期の停止、DNA 合成の遮断、およびアポトーシスの誘導を誘導します。 NKP-1339 は高い腫瘍標的能を持ち、アルブミンやトランスフェリンなどの血清タンパク質に強く結合し、還元腫瘍環境で活性化します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 197723-00-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
NKP-1339(IT-139) is a ruthenium(iii) coordination anticancer compound based on target to transferrin.
References:
[1]. Kuhn PS, et al. Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potential. Dalton Trans. 2014 Nov 11.
[2]. Robert Trondl, et al. ChemInform Abstract: NKP-1339, the First Ruthenium-Based Anticancer Drug on the Edge to Clinical Application.
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *